Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending December 6, 2015

MRI Lesion Detection in Multiple Sclerosis, Comparing conventional and “advanced” techniques

IL-17A in Myasthenia Gravis, Studying associations with sex and disease severity

14bp Polymorphism in Multiple Sclerosis, Could it be a risk factor?

B Cells in Relapsing-Remitting Multiple Sclerosis, Revealing their coordination capabilities

Interferon Beta Stimulated Genes in Multiple Sclerosis, Could they be early biomarkers of treatment response?

More must reads

Must reads for theWeek ending November 29, 2015

Pregnancy After NMOSD Onset, Studying risk factors for miscarriage

Brain Aging Toward Dementia, Assessing decline over time

CAG Expansion in Huntington Disease, Measuring its effect on motor, cognitive, and behavioral scores

Intravenous Methylprednisolone in MS and NMO, Evaluating the effects of subsequent courses

Neuromyelitis Optica Diagnostic Criteria, Assessing their clinical utility

More must reads

Must reads for theWeek ending November 22, 2015

Cognitive Decline in Multiple Sclerosis, Assessing the effects of thalamus atrophy

Detecting Autoantibodies in Multiple Sclerosis, Evaluating the use of electrochemiluminescence assay

Cerebellar Growth in CNS Demyelinating Disease, Does age of onset correlate with volume loss?

Teriflunomide in Relapsing-Remitting MS, Comparing adverse events across studies

Escalation of Therapy in Neuromyelitis Optica Attacks, Do multiple courses of treatment affect outcomes?

More must reads

Must reads for theWeek ending November 15, 2015

HRQOL Following Minor Ischemic Events, Predicting impairment at 3 months

Neurofilament Light Concentration in Alzheimer Disease, Studying associations with cognitive deterioration

Cerebral Amyloid Angiopathy in AD, Defining cognitive associations

Narcolepsy in African Americans, Does ethnicity affect sleep patterns?

Curative Surgery for Epileptic Spasms, Which procedures produce the best outcomes?

More must reads

Must reads for theWeek ending November 8, 2015

Progressive Multifocal Leukoencephalopathy in MS, Evaluating the role of John Cunningham virus

Soluble CD26 and CD30 in MS, Assessing associations with immune responses

Alemtuzumab in Relapsing MS, Does clinical trial data hold up?

Cardiac Events in Fingolimod Initiation, Evaluating events in 850 episodes

Associations Between Symptoms, Community Integration, and Mental Health, Does MS type or level of progression define the patient?

More must reads

Pages